Orateur
Description
Alzheimer’s disease (AD) is related to increasing age. It is mainly characterized by progressive neurodegenerative disease, which damages memory and cognitive function. The cholinergic hypothesis is a key theory used to explain the development of Alzheimer's disease (AD). It suggests that AD results from a decline in the neurotransmitter acetylcholine (ACh). Many AD treatments are based on this hypothesis. The deficits of neurotransmitters such as ACh, serotonin, and norepinephrine occur due to cell death in the brain. Research has shown that reduced neurotransmitter levels in the cholinergic system contribute to cognitive decline and memory loss in AD patients. Acetylcholinesterase (AChE) is the primary enzyme responsible for breaking down ACh.
In recent years, significant attention has been given to developing cholinesterase inhibitors (Acetylcholinesterase and Butyrylcholinesterase) to improve Alzheimer's disease (AD) treatment. Therefore, this study aims to perform a biological evaluation of natural active compounds (Nicotinamide- Curcumin) that inhibit these enzymes. To accomplish this goal, a biological evaluation was conducted against Acetylcholinesterase and Butyrylcholinesterase enzymes, followed by a molecular docking study and drug-likeness assessment. The results suggest that these compounds could serve as promising candidates for Alzheimer's treatment.
